Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Digital health company Liva Healthcare has acquired UK-based Momenta, a provider of digital, virtual, and in-person healthy ...

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (the "Company" or " ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...

Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price rose 0.1% on Tuesday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist Financial ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in ...